PeptideSciences has removed GLP-1 peptides as enforcement pressure grows. We examine industry signals, affiliate warnings, and SS-31 cease and desist actions.
At first glance, GLP‑1 agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) look like another weight‑loss fad. In clinical trials, these drugs slowed stomach emptying, increased feelings of fullness and cut energy intake by about 35 %